President & CEO
Ketan is the founder of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies. Ketan’s work at Tris has led to many discoveries and inventions. Before founding Tris Pharma, Ketan worked for Capsugel (formerly a division of Pfizer) in sales, marketing and business development for eight years. Prior to Capsugel, he spent approximately six years as a pharmaceutical scientist for three different large pharmaceutical companies. Ketan is a pharmacist by education and holds an MS degree in Pharmaceutical Sciences from the University of Oklahoma.
Sally Berry, MD, PhD
Chief Medical Officer
Dr. Sally Berry joined Tris in June 2014 and leads our medical affairs and clinical development group. Sally is a board-certified psychiatrist with a distinguished career in medical affairs and clinical development of many leading products. With more than 25 years of experience, Sally has authored and co-authored more than 20 publications and has successfully contributed to the development of products such as Quillivant® XR, Invega®, Risperdal®, Risperdal Consta®, and Concerta®. She holds an MD and PhD in Pharmacology from Case Western Reserve University and earned an MS in Neurobiology and a BS in Biology from Purdue University.
Senior Vice President, Corporate Development/Acting CFO
Peter joined Tris in April 2010 and leads our licensing and M&A initiatives. Peter brings to Tris a diverse background and an analytical approach steeped in pharmaceutical markets. He is a pharmacist by training and holds an MBA in finance from Rutgers University. After business school, he joined a boutique strategic management consulting firm where he spent six plus years, serving as Vice President for the last three years. His clients included leading pharmaceutical firms such as Pfizer and Novartis, drug distribution companies, and health system firms. Peter then spent six years at Kos Pharmaceuticals, serving for the last two years as Executive Director of Corporate Development and Business Planning prior to Kos’ acquisition by Abbott Labs.
Chief Commercial Officer
Sharon Clarke is an accomplished pharmaceutical industry executive with more than 20 years of direct senior leadership experience in sales, marketing, training, strategic development, business acquisitions and commercial operations. As the President and General Manager of Meda Pharmaceuticals (the leading division of Meda AB, a "Top 50” global specialty pharmaceutical company), Sharon’s deep knowledge of the allergy/respiratory, pain, CNS and ophthalmology markets resulted in successful launches of more than five products that together generated more than $250 million in revenues. She is currently Tris’ Chief Commercial Officer and has been a leader with the company’s first branded product launch, DYANAVEL® XR.
Vice President, Regulatory Affairs
Since July 2014, Norma has led our Regulatory Affairs teams for both brand and generic regulatory operations. She has over 35 years of international and domestic regulatory experience in the pharmaceutical industry and her therapeutic areas of expertise include CNS, respiratory, cardiovascular and endocrinology. Norma received a BS degree from University of Rochester with a double major in Biology and Toxicology and has proven success in NDA and ANDA submissions in her previous leadership roles with Ono Pharma, Celltech Americas, Medeva Americas and Fisons Corporation.
Vice President, Operations & Technical Services
Amanda joined Tris in April 2012 and leads our Operations team, including Supply Chain, Facilities and Engineering, Production and Technical services. Amanda brings to Tris her 20-plus years of experience in the pharmaceutical industry. She has worked on a multitude of dosage forms including metered dose inhalers, nasal products, tablets, capsules, liquids, topicals, and suppositories. She started her career in the Operations environment at Armstrong Pharmaceuticals in Massachusetts and then held senior-level positions at three different generic companies in validation, technical services, and quality assurance. She has a BS in Mechanical Engineering, with a concentration in Manufacturing, from Clarkson University and completed her MBA at Simmons College in Boston.
President, Generic Division
Janet joined Tris in May 2013 and leads the generic business unit. She brings a diverse background to Tris. Janet spent the first 12 years of her career working across multiple functional areas within GE and PepsiCo divisions in industries spanning consumer durables, financial services, and hospitality. In 1999 she joined Amerisource, eventually heading up the generics group for Amerisource and then AmerisourceBergen. Since then, Janet has held senior management positions with smaller and mid-sized generic pharmaceutical companies. She holds an MBA from the Schulich School of Business at York University and a BA from Western University.
Senior Vice President, Human Resources
Cheryl has led and managed all human resources activities at Tris since 2011. With over 20 years of human resources experience, she is highly experienced in ensuring that the workforce maintains a high level of productivity during times of change and accelerated growth. Most recently, Cheryl served as president of Capella Consultants LLC, where she led the human resources and management consulting groups. Prior to Capella, Cheryl spent more than 15 years at Sovereign Bank, the last seven years as Executive Vice President, human resources. She is active in the Central New Jersey business community as a volunteer and was a recipient of the HR Person of the Year Award from the Society of Human Resources Management. She earned a BS in business administration, summa cum laude, from the University of Richmond, Virginia.
Nemi Jain, PhD
Vice President, Research & Development
Nemi brings extensive pharmaceutical industry experience in drug development in general and formulation development in particular. He worked at Bristol-Myers Squibb for more than 30 years as a technical leader and is credited with successful development, regulatory approval, and launch of several key products. More recently, he was involved with development and approval of a novel dosage form made using 3-DP technology at Aprecia Pharmaceuticals Co. He holds a PhD in Pharmaceutical Chemistry from the University of Kansas and received his undergraduate degree in Pharmaceutical Technology from the University of Bombay.